1	Deep learning for subtypes identification of pure seminoma of the
2	testis
3 4	Kirill E. Medvedev <sup>1,*</sup> , Paul H. Acosta <sup>2</sup> , Liwei Jia <sup>3</sup> , Nick V. Grishin <sup>1,4</sup>
5	
6	<sup>1</sup> Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, TX 75390,
7	USA
8	<sup>2</sup> Lyda Hill Department of Bioinformatics, University of Texas Southwestern Medical Center,
9	Dallas, TX 75390, USA
10	<sup>3</sup> Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390,
11	USA
12	<sup>4</sup> Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX
13	75390, USA
14	* Corresponding author
15	E-mail: Kirill.Medvedev@UTSouthwestern.edu

### 17 Abstract

18 The most critical step in the clinical diagnosis workflow is the pathological evaluation of each 19 tumor sample. Deep learning is a powerful approach that is widely used to enhance diagnostic 20 accuracy and streamline the diagnosis process. In our previous study using omics data, we 21 identified two distinct subtypes of pure seminoma. Seminoma is the most common histological 22 type of testicular germ cell tumors (TGCTs). Here we developed a deep learning decision making 23 tool for the identification of seminoma subtypes using histopathological slides. We used all 24 available slides for pure seminoma samples from The Cancer Genome Atlas (TCGA). The 25 developed model showed an area under the ROC curve of 0.896. Our model not only confirms the 26 presence of two distinct subtypes within pure seminoma but also unveils the presence of 27 morphological differences between them that are imperceptible to the human eye.

28

29 **Keywords:** bioinformatics, computational biology, deep learning, seminoma, subtypes

#### 31 Introduction

32 Testicular seminoma is the most prevalent histological subtype of testicular germ cell tumors 33 (TGCT), accounting for the highest incidence rate among all types of testicular cancer<sup>1</sup>. TGCTs 34 are the most frequent type of solid cancer affecting men between the ages of 15 and 44<sup>1</sup> and rank second among adult cancers in terms of life years lost per person dying of cancer  $^2$ . The treatment 35 36 protocol for seminoma typically includes orchiectomy followed by either platinum-based 37 chemotherapy utilizing cisplatin or radiation therapy <sup>3</sup>. While current treatments for seminoma 38 have high efficacy and survival rates for patients, they also carry the risk of around 40 severe and 39 potentially life-threatening long-term side effects, such as infertility, neurotoxicity, hypercholesterolaemia, secondary cancers and death <sup>4</sup>. The presence of elevated platinum 40 41 concentrations from chemotherapy in the bloodstream can persist at levels up to 1,000 times higher 42 than the norm for a duration of 20 years, potentially contributing to various long-term effects <sup>5</sup>. 43 Prolonged exposure to elevated platinum levels can result in vascular damage and is highly likely to be linked with the onset of neuropathy <sup>6</sup> and cardiovascular diseases <sup>7</sup>. After undergoing 44 45 chemotherapy, patients with TGCT exhibited a decrease of 3.6 dB in hearing for each additional 100 mg/m2 of cumulative cisplatin dose<sup>8,9</sup>. Relapse occurs in approximately 20% of seminoma 46 47 cases, and the underlying reasons for this phenomenon remain unclear <sup>10</sup>, however there are several 48 well-known seminoma risk factors such as rete testis, lymphovascular invasion, cryptorchidism, mutations in KRAS and KIT genes <sup>11,12</sup>. Patients experiencing a relapse will receive further 49 50 treatment involving chemotherapy and radiation therapy, which intensify the side effects 51 considerably. Recently we discovered two distinct subtypes of pure seminoma of the testis based on omics data <sup>13,14</sup>. Two identified seminoma subtypes revealed significant differences in the rates 52 53 of loss of heterozygosity, the level of expression of lncRNA associated with cisplatin resistance,

54 the activity of double stranded DNA breaks repair mechanisms and the pluripotency stage. 55 Seminoma subtype 1 exhibits a higher pluripotency state, while subtype 2 reveals attributes of 56 reprogramming into non-seminomatous lineages of TGCT, which are more aggressive and require 57 higher dose of chemotherapy drugs <sup>3</sup>. We showed that subtype 1 of seminoma, which is less 58 differentiated, exhibits an immune microenvironment characterized by a significantly lower immune score and a larger fraction of neutrophils <sup>14</sup>. These features are indicative of the immune 59 60 microenvironment at an early developmental stage. Moreover, subtype 2 revealed the 61 overexpression of genes related to the senescence-associated secretory phenotype, which might be 62 one of the reasons for seminoma immunotherapy failure <sup>14</sup>. Therefore, we suggested that seminoma 63 subtype 2 might require an adjustment to its treatment strategy. The development of subtype-64 specific therapy for seminoma can reduce the risk of chemotherapy overtreatment in TGCT 65 patients and enhance the quality of life for TGCT survivors.

Deep learning (DL) is a powerful tool capable of extracting previously hidden information directly from routine histopathology images of cancer tissue, simplifying, speeding up, and automating clinical decision-making <sup>15</sup>. The performance of modern DL methods applied to pathological data often exceeds that of human pathologists <sup>15</sup>. Most pathologists work under conditions of an extreme work overload <sup>16</sup>. An overworked pathologist can result in the misinterpretation of pathological data that affects patients' health and quality of life. DL applications aim to simplify and speed up routine pathological workflows and reduce pathologists' overload burden.

Here, we have developed a DL-based approach to examine potential histopathologic differences between seminoma subtypes that were previously identified using omics data. Additionally, our goal is to utilize this approach to detect and classify these subtypes based on histopathological slides. Our findings demonstrate that pure seminoma subtypes cannot be classified solely based on

- 77 histopathological features. However, the developed DL-based model revealed histopathological
- 78 differences between these subtypes, as indicated by the area under the ROC curve (AUC) values.

#### 80 Materials and Methods

#### 81 **Data set preparation**

82 We used all hematoxylin and eosin (H&E) histopathological slides available at The Cancer 83 Genome Atlas (TCGA) data portal (TCGA-TGCT study) for 64 pure seminoma, which comprised 84 156 whole slide images (WSIs). Based on our previous study, we assigned 40 out of 64 samples 85 to seminoma subtype 1 (101 WSIs) and the remaining 24 samples to seminoma subtype 2 (55 86 WSIs) <sup>13</sup>. Pure seminoma regions of interest (ROIs) were designated and verified for each WSI by 87 a genitourinary specialized pathologist using Aperio ImageScope version 12.1. During our analysis 88 of pure seminoma H&E slides from the TCGA portal, we identified two samples (TCGA-2G-89 AAG9, TCGA-2G-AAH0), initially reported as pure seminoma. However, upon further 90 examination, they should be reclassified as mixed GCT since they contain other types of GCT 91 (teratoma and embryonal carcinoma) in addition to seminoma (Fig.1). Consequently, these cases 92 were removed from our data set.

93 Verified ROIs were subsequently split into smaller tiles (300x300 pixels) at a 20X magnification with a 50% overlap using DeepPath package <sup>17</sup> (Fig. 2). Tiles that contained more than 20% of 94 95 background were removed. We conducted a manual check and excluded tiles of poor quality that 96 contained out of focus images and defects, such as scratches, dirt and folded tissue. TGCTs are relatively uncommon compared to other cancers<sup>2</sup>, and therefore histopathological data availability 97 98 is limited. Thus, image data augmentation technique was applied to the dataset of tiles to create 99 synthetic variations of the images and expand the training dataset. We used the following augmentations from the Imgaug library <sup>18</sup>: random rotation by 0°, 90°, 180°, 270°, random increase 100 101 and decrease of contrast, brightness and saturation.

#### 103 **Training the model**

104 We conducted all computational experiments at the BioHPC computing facility (Lyda Hill 105 Department of Bioinformatics, UT Southwestern Medical Center, TX, USA). TensorFlow package <sup>19</sup> version 2.5.0 was used for developing DL model based on Convolution Neural Networks 106 107 (CNNs) method. The software stack for GPU acceleration included CUDA 11.2 and cuDNN 8.1. 108 We employed a convolutional neural network with MobileNet<sup>20</sup> architecture that includes 85 109 convolutional layers. During the training top 29 convolutional layers were kept frozen (fixed). We 110 used sigmoid activation and the Binary Cross Entropy loss function, which is used when there are 111 only two label classes (seminoma subtypes 1 and 2). The Adam optimizer was selected due to its superior performance in terms of both speed of convergence and accuracy <sup>21</sup> with a learning rate 112 113 of 0.001. Due to imbalanced dataset we used subtype (class) weights calculated as follows: 114  $w_1 = (1 / s_1) * (total / 2.0)$  and  $w_2 = (1 / s_2) * (total / 2.0)$ , where  $s_1, s_2$  – number of tiles for 115 subtypes 1 and 2, and total is overall number of tiles. The neural network was initialized from ImageNet-pretrained <sup>22</sup> weights. Model training was performed for 20 epochs with 3-fold cross-116 117 validation. Tiles belonging to a particular sample were included only in one subset of data – either 118 training or validation.

#### 119 **Statistical analysis**

We used the area under receiver operating characteristics (ROC, AUC) curve and accuracy as evaluation metrics to measure the tile-level and sample-level performance of the developed model. The ROC curve was defined as false-positive rate (1-specificity) on the x-axis versus true positive rate (sensitivity or recall) on the y-axis. Specificity = TN / (TN+FP), Sensitivity = TP / (TP+FN), Accuracy = (TP+TN) / (TP+FP+TN+FN), where FP, FN, TP and TN are false positives, false negatives, true positives and true negatives, respectively.

#### 126 Nuclei segmentation

127 Nuclei segmentation of seminoma tiles was conducted using TIA Toolbox 1.4.1 <sup>23</sup>. We applied the 128 HoVer-Net model <sup>24</sup> that has been already trained on the PanNuke dataset <sup>25</sup> and incorporated in 129 the TIA Toolbox. The calculation of nuclei size was performed using the Python library scikit-130 image <sup>26</sup>.

131

### 132 **Results and Discussion**

133 Overview of the whole experiment is shown on Figure 3. The performance of the model was 134 evaluated using the area under the ROC curve metric (Fig. 4B) and confusion matrices (Fig. 4C). 135 The developed model showed highest AUC = 0.896 (Fig. 4B). Trained model for identification of 136 pure seminoma subtypes is available GitHub in open access at 137 (https://github.com/kirmedvedev/seminoma-subtypes).

138 Every sample of solid tumor undergoes a detailed analysis by a professional pathologist, which 139 includes verifying the presence of cancer tissue and annotating tumor regions. This is a crucial 140 process in the clinical diagnosis routine. Inaccuracies in pathology reports can critically affect the 141 quality of patient care. An audit of pathology reports showed that if a sample size of 50 gives a 142 sample error rate of 2% there is a 95% probability that the true error rate is up to 10.9% <sup>27</sup>. 143 Moreover, up to one-third of clinicians do not always understand pathology reports, leading 144 tomisinterpretation and uncertainty in clinical diagnosis <sup>28</sup>. DL approaches applied to 145 histopathological slide images aim to speed up the diagnosis significantly and simplify their 146 implementation into the clinical workflow. TGCTs and seminoma histopathology images, in 147 particular, have not been extensively studied using DL method, and very limited studies are available nowadays. DL approached were previously applied to TGCTs WSIs for detecting tumor-148

infiltrating lymphocytes <sup>29</sup>, detecting lymphovascular invasion <sup>30</sup> and developing tumor/normal
 classifier <sup>31</sup>.

151 In this report, we present our first version of the DL decision making tool for the identification of 152 pure seminoma subtypes using histopathological slides. We hypothesize that considering 153 seminoma subtypes during the development of a treatment strategy may improve its clinical 154 management, and the implementation of the developed model will enhance diagnostic accuracy 155 and reduce potential errors. This is especially crucial when subtypes cannot be distinguished by a 156 pathologist which is the case with pure seminoma. The developed model showed the capability to 157 distinguish pure seminoma subtypes (Table 1), confirming our previous findings <sup>13,14</sup>. This also 158 indicates the presence of morphological differences between seminoma subtypes. We believe that 159 the morphological differences may be due to the difference in the immune microenvironment 160 between the two subtypes. Previously, using deconvolution methods for bulk RNA-seq data of the 161 seminoma subtypes from TCGA, we showed that the neutrophil fraction is significantly higher for 162 subtype 1<sup>14</sup>. Moreover, according to TCGA clinical data, seminoma subtype 2 revealed an 163 increased occurrence of lymphovascular invasion, with a rate of 43% compared to 25% for subtype 164 1. We also conducted nuclei segmentation and calculated nuclei sizes for both subtypes. Our analysis revealed no significant differences in nuclei size distributions between the seminoma 165 166 subtypes (Fig. 5A, B).

However, the accuracy of identifying subtype 1 samples by the developed model is higher than of subtype 2 samples. This could be due to certain limitations of the model. First, the current model was developed using a limited dataset. Second, only one architecture type of CNN was tested. In future work, this model should be verified using an expanded dataset and several addition CNN architecture types.

# 172 **Table 1. Prediction of seminoma subtypes using developed DL model.** S1 – subtype 1, S2 –

173 subtype 2.

Sample ID	Transcriptomic subtype	DL model prediction	Sample ID	Transcriptomic subtype	DL model prediction
TCGA-XY-A9T9	<b>S</b> 1	S1	TCGA-2G-AAH3	<b>S</b> 1	S1
TCGA-WZ-A7V4	<b>S</b> 1	S1	TCGA-SB-A6J6	<b>S</b> 1	S1
TCGA-2G-AAEX	<b>S</b> 1	S1	TCGA-2G-AAHP	<b>S</b> 1	S1
TCGA-2G-AAF6	<b>S</b> 1	S1	TCGA-VF-A8AB	S2	<b>S</b> 1
TCGA-S6-A8JX	<b>S</b> 1	S1	TCGA-ZM-AA05	S2	S2
TCGA-XY-A89B	<b>S</b> 1	S1	TCGA-XE-AANR	S2	S2
TCGA-2G-AAFG	<b>S</b> 1	S2	TCGA-ZM-AA0D	S2	S2
TCGA-2G-AAH8	<b>S</b> 1	S1	TCGA-2G-AAHN	S2	S2
TCGA-2G-AAF1	<b>S</b> 1	<b>S</b> 1	TCGA-4K-AAAL	S2	<b>S</b> 1
TCGA-WZ-A7V3	<b>S</b> 1	<b>S</b> 1	TCGA-VF-A8AE	S2	<b>S</b> 1
TCGA-S6-A8JY	<b>S</b> 1	S1	TCGA-ZM-AA0B	S2	S2
TCGA-VF-A8AA	<b>S</b> 1	S1	TCGA-XE-AAOF	S2	<b>S</b> 1
TCGA-WZ-A7V5	<b>S</b> 1	S1	TCGA-ZM-AA0F	S2	S2
TCGA-SO-A8JP	S1	<b>S</b> 1	TCGA-2G-AAHA	S2	<b>S</b> 1
TCGA-XE-A8H4	S1	<b>S</b> 1	TCGA-2G-AAHT	S2	<b>S</b> 1
TCGA-XE-A8H5	S1	<b>S</b> 1	TCGA-4K-AA1H	S2	S2
TCGA-XE-A9SE	S1	<b>S</b> 2	TCGA-VF-A8A9	S2	S2
TCGA-XE-AANJ	S1	<b>S</b> 1	TCGA-VF-A8AC	S2	<b>S</b> 1
TCGA-XE-AANV	S1	<b>S</b> 1	TCGA-XE-AAO6	S2	S2
TCGA-XE-AAO3	<b>S</b> 1	S1	TCGA-XE-AAOL	S2	S2
TCGA-YU-A90Q	<b>S</b> 1	S2	TCGA-YU-A90S	S2	<b>S</b> 1
TCGA-YU-A90W	<b>S</b> 1	S1	TCGA-ZM-AA06	S2	S2
TCGA-YU-A912	<b>S</b> 1	S2	TCGA-ZM-AA0E	S2	S2
TCGA-S6-A8JW	<b>S</b> 1	S1	TCGA-ZM-AA0H	<b>S</b> 2	<b>S</b> 1
TCGA-2G-AAEW	<b>S</b> 1	S1	TCGA-ZM-AA0N	S2	S2
TCGA-2G-AAF4	<b>S</b> 1	<b>S</b> 1	TCGA-2G-AAHL	S2	<b>S</b> 1
TCGA-4K-AA1I	<b>S</b> 1	<b>S</b> 2	TCGA-4K-AA1G	<b>S</b> 2	S2
TCGA-2G-AAFE	<b>S</b> 1	S1			

174

# 175 **Conclusion**

176 In this study we developed a DL-based model to investigate the presence of histopathological 177 distinctions between two previously identified subtypes of pure seminoma, which were initially 178 characterized using omics data. The objective was to provide further evidence supporting the 179 existence of seminoma subtypes. The results of our analysis revealed histopathological differences 180 between the two subtypes of pure seminoma. These findings provide additional confirmation and 181 support the notion that seminoma can be further stratified into distinct subtypes. These results 182 highlight the potential of histopathological analysis as a complementary tool in subtype 183 classification, offering additional insights alongside other omics-based approaches. However, our 184 study also provides evidence suggesting that pure seminoma subtypes cannot be reliably classified 185 based solely on histopathological features. Despite the observed histopathological differences 186 between the subtypes, these distinctions alone are not sufficient for accurate subtype classification.

187

### 188 Funding

The study is supported by the grants from the National Institute of General Medical Sciences of the National Institutes of Health GM127390 (to N.V.G.), the Welch Foundation I-1505 (to N.V.G.), and the National Science Foundation DBI 2224128 (to N.V.G.).

192

#### 193 Acknowledgements

194 Authors are grateful to Dr. Satwik Rajaram for helpful discussions. Authors are grateful to TCGA 195 data portal for providing access to TGCT datasets. This research was supported in part by the 196 computational resources provided by the BioHPC computing facility located in the Lyda Hill 197 Department of **Bioinformatics**, UT Southwestern Medical Center. TX. URL: 198 https://portal.biohpc.swmed.edu

# 199

# 200 Conflict of interest statement

201 The authors declare that there are no competing interests associated with the manuscript.

202

# 203 Ethics statement

204 Not applicable.

Figure 1. Slide images of samples containing additional types of GCT. (A) TCGA-2G-AAG9.

# 206 Figures legends

208	(B) TCGA-2G-AAH0. Teratoma tissue is shown in green, embryonal carcinoma in cyan.
209	
210	Figure 2. Extraction of tiles from annotated whole slide images (WSI) of two subtypes of pure
211	seminoma.

212

207

- 213 Figure 3. Overview of dataset preparation, training and validation process.
- 214
- 215 Figure 4. Validation statistics. (A) Validation accuracy. (B) Receiver operating characteristic

216 (ROC) curves for validation set. (C) Normalized confusion matrices.

- 217
- 218 Figure 5. Nuclei segmentation results. (A) Visualization of nuclei segmentation results. (B)
- 219 Comparison of seminoma cell nuclei size distribution between two subtypes.
- 220

### 221 **References**

 Ghazarian AA, Trabert B, Devesa SS, McGlynn KA. Recent trends in the incidence of testicular germ cell tumors in the United States. *Andrology*. Jan 2015;3(1):13-8. doi:10.1111/andr.288

Data from: Surveillance, Epidemiology, and End Results (SEER) Program SEER\*Stat
 Database: Incidence - SEER Research Data, 8 Registries, Nov 2021 Sub (1975-2020) - Linked To
 County Attributes - Time Dependent (1990-2020) Income/Rurality, 1969-2020 Counties, National
 Cancer Institute, DCCPS, Surveillance Research Program, released April 2023, based on the
 November 2022 submission.

3. Shin YS, Kim HJ. Current management of testicular cancer. *Korean J Urol.* Jan 2013;54(1):2-10. doi:10.4111/kju.2013.54.1.2

4. Chovanec M, Lauritsen J, Bandak M, et al. Late adverse effects and quality of life in
survivors of testicular germ cell tumour. *Nat Rev Urol.* Apr 2021;18(4):227-245.
doi:10.1038/s41585-021-00440-w

5. Gerl A, Schierl R. Urinary excretion of platinum in chemotherapy-treated long-term
survivors of testicular cancer. *Acta Oncol*. 2000;39(4):519-22. doi:10.1080/028418600750013447
6. Sprauten M, Darrah TH, Peterson DR, et al. Impact of long-term serum platinum
concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. *J Clin Oncol.* Jan 20 2012;30(3):300-7. doi:10.1200/JCO.2011.37.4025

240 7. Boer H, Proost JH, Nuver J, et al. Long-term exposure to circulating platinum is associated
241 with late effects of treatment in testicular cancer survivors. *Ann Oncol.* Nov 2015;26(11):2305-10.
242 doi:10.1093/annonc/mdv369

8. Haugnes HS, Stenklev NC, Brydoy M, et al. Hearing loss before and after cisplatin-based
chemotherapy in testicular cancer survivors: a longitudinal study. *Acta Oncol.* Aug
2018;57(8):1075-1083. doi:10.1080/0284186X.2018.1433323

Frisina RD, Wheeler HE, Fossa SD, et al. Comprehensive Audiometric Analysis of
Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of AdultOnset Cancer. *J Clin Oncol.* Aug 10 2016;34(23):2712-20. doi:10.1200/JCO.2016.66.8822

Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma
managed by surveillance: a pooled analysis. *J Clin Oncol.* Nov 15 2002;20(22):4448-52.
doi:10.1200/JCO.2002.01.038

Boormans JL, Mayor de Castro J, Marconi L, et al. Testicular Tumour Size and Rete Testis
Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients
Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. *Eur Urol.*Mar 2018;73(3):394-405. doi:10.1016/j.eururo.2017.09.025

Fukawa T, Kanayama HO. Current knowledge of risk factors for testicular germ cell
tumors. *Int J Urol.* Apr 2018;25(4):337-344. doi:10.1111/iju.13519

Medvedev KE, Savelyeva AV, Chen KS, Bagrodia A, Jia L, Grishin NV. Integrated
 Molecular Analysis Reveals 2 Distinct Subtypes of Pure Seminoma of the Testis. *Cancer Inform.*

260 2022;21:11769351221132634. doi:10.1177/11769351221132634

14. Savelyeva AV, Medvedev KE. Seminoma subtypes differ in the organization and
functional state of the immune microenvironment. *3 Biotech*. Mar 2023;13(3):110.
doi:10.1007/s13205-023-03530-1

Echle A, Rindtorff NT, Brinker TJ, Luedde T, Pearson AT, Kather JN. Deep learning in
cancer pathology: a new generation of clinical biomarkers. *Br J Cancer*. Feb 2021;124(4):686696. doi:10.1038/s41416-020-01122-x

Fritzsche FR, Ramach C, Soldini D, et al. Occupational health risks of pathologists--results
from a nationwide online questionnaire in Switzerland. *BMC Public Health*. Dec 6 2012;12:1054.
doi:10.1186/1471-2458-12-1054

270 17. Coudray N, Ocampo PS, Sakellaropoulos T, et al. Classification and mutation prediction
271 from non-small cell lung cancer histopathology images using deep learning. *Nat Med.* Oct
272 2018;24(10):1559-1567. doi:10.1038/s41591-018-0177-5

18. *imgaug*. 2020. Accessed accessed 01-Feb-2022. <u>https://github.com/aleju/imgaug</u>

Abadi M BP, Chen J, Chen Z, Davis A, Dean J, Devin M, Ghemawat S, Irving G, Isard M,
Kudlur M. TensorFlow: a system for Large-Scale machine learning. presented at: In12th USENIX
symposium on operating systems design and implementation (OSDI 16); 2016;

20. Andrew G. Howard MZ, Bo Chen, Dmitry Kalenichenko, Weijun Wang, Tobias Weyand,
Marco Andreetto, Hartwig Adam. MobileNets: Efficient Convolutional Neural Networks for
Mobile Vision Applications. *arXiv*. 2017;doi:<u>https://doi.org/10.48550/arXiv.1704.04861</u>

280 21. Kingma DP BJ. Adam: A method for stochastic optimization. *arXiv*.
281 2014;doi:<u>https://doi.org/10.48550/arXiv.1412.6980</u>

282 22. Deng J DW, Socher R, Li LJ, Li K, Fei-Fei L. Imagenet: A large-scale hierarchical image 283 database. presented at: In 2009 IEEE conference on computer vision and pattern recognition 2009

284 Jun 20; 2009;

285 23. Pocock J, Graham S, Vu QD, et al. TIAToolbox as an end-to-end library for advanced
286 tissue image analytics. *Commun Med (Lond)*. 2022;2:120. doi:10.1038/s43856-022-00186-5

287 24. Graham S, Vu QD, Raza SEA, et al. Hover-Net: Simultaneous segmentation and
288 classification of nuclei in multi-tissue histology images. *Med Image Anal*. Dec 2019;58:101563.
289 doi:10.1016/j.media.2019.101563

25. Jevgenij Gamper NAK, Ksenija Benes, Simon Graham, Mostafa Jahanifar, Syed Ali
291 Khurram, Ayesha Azam, Katherine Hewitt, Nasir Rajpoot. PanNuke Dataset Extension, Insights
292 and Baselines. *arXiv*. 2020;doi:10.48550/arXiv.2003.10778

293 26. van der Walt S, Schonberger JL, Nunez-Iglesias J, et al. scikit-image: image processing in
294 Python. *PeerJ*. 2014;2:e453. doi:10.7717/peerj.453

295 27. Ramsay AD. Errors in histopathology reporting: detection and avoidance. *Histopathology*.
296 Jun 1999;34(6):481-90. doi:10.1046/j.1365-2559.1999.00719.x

28. Mirham L HJ, Yousef GM. Addressing the diagnostic miscommunication in pathology:
old challenges and innovative solutions. *American Journal of Clinical Pathology*.
2021;156(4):521-528. doi:https://doi.org/10.1093/ajcp/aqab014

29. Linder N, Taylor JC, Colling R, et al. Deep learning for detecting tumour-infiltrating
lymphocytes in testicular germ cell tumours. *J Clin Pathol*. Feb 2019;72(2):157-164.
doi:10.1136/jclinpath-2018-205328

30. Ghosh A, Sirinukunwattana K, Khalid Alham N, et al. The Potential of Artificial
304 Intelligence to Detect Lymphovascular Invasion in Testicular Cancer. *Cancers (Basel)*. Mar 16
305 2021;13(6)doi:10.3390/cancers13061325

306 31. Noorbakhsh J, Farahmand S, Foroughi Pour A, et al. Deep learning-based cross-307 classifications reveal conserved spatial behaviors within tumor histological images. *Nat Commun.* 

308 Dec 11 2020;11(1):6367. doi:10.1038/s41467-020-20030-5

# 311 Figures



- 313 Figure 1
- 314



315

316 Figure 2



319 Figure 3

320



321

322 Figure 4





325 Figure 5



B

A

# WSI of seminoma subtype 1

# WSI of seminoma subtype 2











